David M Waterhouse MD

Oncology•Cincinnati, OH

Hematologic Oncology, Thoracic Cancer

Physician

Join to View Full Profile

3301 Mercy Health BlvdSte 100Cincinnati, OH 45211
Phone+1 513-751-2145
Fax+1 513-751-1848

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 1989 - 1991
UMass Chan Medical SchoolResidency, Internal Medicine, 1985 - 1988
University of Massachusetts Medical SchoolClass of 1985

Certifications & Licensure

OH State Medical License 1993 - 2025
MA State Medical License 1986 - 2024
KY State Medical License 1997 - 2018
MI State Medical License 1989 - 1996
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Top MD Consumers Checkbook

Clinical Trials

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
COMPLETED
PHASE1, PHASE2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Start of enrollment: 2015 Apr 29
Completed
Phase 2
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer Start of enrollment: 2015 Jul 01
Terminated
Phase 2
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
Pan Tumor Rollover Study Start of enrollment: 2019 Aug 09
RECRUITING
PHASE2
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations Start of enrollment: 2020 Mar 11
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.
Adrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, Anne-Marie C Dingemans, Giannis Mountzios
Future Oncology. 2025-03-24
Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US.
Divyan Chopra, David M Waterhouse, Ihtisham Sultan, Björn Stollenwerk
Current Oncology. 2025-03-05
1 citations
State of Geographic Access to Cancer Treatment Trials in the United States: Are Studies Located Where Patients Live?
M Kelsey Kirkwood, Caroline Schenkel, Dominique C Hinshaw, Suanna S Bruinooge, David M Waterhouse
JCO Oncology Practice. 2025-03-01

Press Mentions

OHC's Waterhouse Feels Privileged to Share in Oncology Patients’ Highs and LowsFebruary 26th, 2021
Oncology Care Model Supports Practice & Benefits Medicare's Bottom LineOctober 23rd, 2019
Increasing Biomarker Testing Rates for Patients with NSCLCDecember 9th, 2023